| P6099 | clinical trial phase | phase III clinical trial | Q42824827 |
| P17 | country | India | Q668 |
| P582 | end time | 2018-02-07 | |
| P921 | main subject | Hepatitis C virus | Q708693 |
| P1050 | medical condition | hepatitis | Q131742 |
| | hepatitis C | Q154869 |
| | hepatitis A | Q157661 |
| P2899 | minimum age | 18 | |
| P1132 | number of participants | 130 | |
| P4844 | research intervention | sofosbuvir | Q2502747 |
| P6153 | research site | Institute of Liver and Biliary Sciences | Q6040494 |
| | Sanjay Gandhi Post Graduate Institute of Medical Sciences | Q7418428 |
| | All India Institute of Medical Sciences, Patna | Q15179382 |
| | YRG Care | Q85852475 |
| P8005 | research subject recruitment status | completed | Q76651189 |
| P859 | sponsor | Gilead Sciences | Q663596 |
| P580 | start time | 2017-03-23 | |
| P8363 | study type | interventional study | Q78089383 |
| P1476 | title | A Phase 3, Open-label Study to Investigate the Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks in Subjects With Chronic Hepatitis C Virus (HCV) Infection | |